➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Boehringer Ingelheim
McKinsey
Harvard Business School
McKesson

Last Updated: January 23, 2021

DrugPatentWatch Database Preview

Pfizer Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Pfizer

Drugs and US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-001 Oct 31, 2008 AB RX Yes No 7,807,715   Start Trial Y   Start Trial
Pfizer PFIZERPEN VK penicillin v potassium TABLET;ORAL 061836-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Pfizer IBRANCE palbociclib TABLET;ORAL 212436-001 Nov 1, 2019 RX Yes No RE47739   Start Trial Y Y   Start Trial
Pfizer TROVAN trovafloxacin mesylate TABLET;ORAL 020759-001 Dec 18, 1997 DISCN No No   Start Trial   Start Trial
Pfizer MODERIL rescinnamine TABLET;ORAL 010686-006 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-002 Feb 26, 1996 5,030,456   Start Trial
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-002 Apr 26, 1994 5,082,668   Start Trial
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-001 Jan 29, 1992 5,082,668   Start Trial
Pfizer XELJANZ tofacitinib citrate SOLUTION;ORAL 213082-001 Sep 25, 2020 7,265,221   Start Trial
Pfizer Pharms ACCURETIC hydrochlorothiazide; quinapril hydrochloride TABLET;ORAL 020125-003 Dec 28, 1999 4,344,949*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 50 mg/0.2 mg ➤ Subscribe 2009-06-29
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe 2018-02-02
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe 2018-02-02
➤ Subscribe Capsules 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg ➤ Subscribe 2008-12-30
➤ Subscribe Extended-release Tablets 11 mg ➤ Subscribe 2016-11-07
➤ Subscribe Capsules 5 mg and 10 mg ➤ Subscribe 2005-06-21
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2005-02-07
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2011-06-17
➤ Subscribe Oral Suspension 100 mg/5 mL ➤ Subscribe 2009-08-03
➤ Subscribe Injection 2 mg/mL, 100 mL bag ➤ Subscribe 2009-12-29
➤ Subscribe Delayed-release Tablets 75 mg/0.2 mg ➤ Subscribe 2008-11-28
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe 2018-01-29
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe 2018-01-29
➤ Subscribe Capsules 75 mg, 100 mg and 125 mg ➤ Subscribe 2019-02-04
➤ Subscribe Extended-release Tablets 4 mg and 8 mg ➤ Subscribe 2012-10-31
➤ Subscribe Oral Solution 20 mg/mL ➤ Subscribe 2010-05-19
➤ Subscribe Injection 20 mg/mL, 2 mL and 5 mL vials ➤ Subscribe 2004-07-26
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe 2014-05-01
➤ Subscribe Tablets 600 mg ➤ Subscribe 2005-12-21
➤ Subscribe Injection 2 mg/mL, 300 mL bag ➤ Subscribe 2009-09-01
➤ Subscribe Tablets 5 mg ➤ Subscribe 2016-11-07

Supplementary Protection Certificates for Pfizer Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1380301 CA 2009 00017 Denmark   Start Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
2822953 132019000000116 Italy   Start Trial PRODUCT NAME: LORLATINIB(LORVIQUA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1355, 20190508
1214076 49/2008 Austria   Start Trial PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
0565634 06C0030 France   Start Trial PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
1666481 PA2017025 Lithuania   Start Trial PRODUCT NAME: TOFACITINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALE, ISKAITANT CITRATO DRUSKAAA; REGISTRATION NO/DATE: EU/1/17/1178 20170322
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Mallinckrodt
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.